RARA CRAFT DATABASE for FDA Medical Devices
510(k)K180041

FDA DEVICE FACTS

BioCode Gastrointestinal Pathogen Panel (GPP)

Applied BioCode, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATESeptember 28, 2018PRODUCT CODEPCH

Indications for use

The BioCode Gastrointestinal Pathogen Panel (GPP) is a qualitative, gastrointestinal microorganism multiplexed nucleic acid-based assay capable of detecting of nucleic acids from the following organisms in unpreserved stool and Cary-Blair media: · Adenovirus 40/41 · Clostridium difficile (C. difficile · Campylobacter (C. jejuni, C. coli) ) toxin A/B (from fresh specimens only) · Cryptosporidium (C. parvum, C. hominis)

· Entamoeba histolytica

· Escherichia coli (E. coli) O157

· Enterotoxigenic E. coli (ETEC) LT/ST

· Enteroaggregative E. coli (EAEC)

· Giardia lamblia (also known as G. intestinalis and G. duodenalis)

· Norovirus GI/GII

· Rotavirus A

· Salmonella spp.

· Shiga-like Toxin producing E. coli (STEC) stx1/stx2

· Shigella (S. boydii, S. sonnei, S. flexneri, S. dysenteriae)/EIEC

· Vibrio spp. (V. cholerae, V. parahaemolyticus, V. vulnificus), specific identification of V. parahaemolyticus

· Yersinia enterocolitica

The BioCode Gastrointestinal Pathogen Panel (GPP) is indicated as an aid in the diagnosis of specific agents of gastrointestinal illness and results are meant to be used in conjunction with other clinical, laboratory, and epidemiological data. Positive results do not rule out co-infection with organisms not included in the BioCode Gastrointestinal Pathogen Panel (GPP). The agent detected may not be the cause of patient illness. Negative results in the setting of clinical illness compatible with gastroenteritis may be due to infection by pathogens that are not detected by this test or non-infectious causes such as ulcerative colitis, irritable bowel syndrome, or Crohn's disease. Concomitant culture is necessary for organism recovery and further typing of bacterial agents. This device is not intended to monitor or guide treatment for C. difficile infection. Due to the small number of positive specimens collected for certain organisms during the prospective clinical study, performance characteristics for Campylobacter spp., E. coli O157, Shigella/EIEC, Yersinia enterocolitica, and Adenovirus 40/41 were established primarily with retrospective clinical specimens. Performance characteristics for Entamoeba histolytica, and Vibrio spp. (V. parahaemolyticus, V. vulnificus, and Vibrio cholerae) were established primarily using contrived clinical specimens. Indication(s) for use: Same as intended use. 1. Special conditions for use statement(s): For prescription use only. 2. Special instrument requirements: For use with the BioCode MDx 3000 instrument.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 26, 2026